Attached files

file filename
EX-99.1 - PRESS RELEASE DATED APRIL 17, 2013 - GUIDED THERAPEUTICS INCex99one.htm

 

 

SECURITIES AND EXCHANGE COMMISSION

 

 

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event) April 17, 2013; (April 17, 2013)

 

GUIDED THERAPEUTICS, INC.

 (Exact Name of Registrant as Specified in Its Charter)

 

     
Delaware 0-22179 58-2029543
(State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification No.)
Incorporation)    

 

 

   

5835 Peachtree Corners East, Suite D

Norcross, Georgia

(Address of Principal Executive Offices)

30092

(Zip Code)

 

Registrant's Telephone Number, Including Area Code:     (770) 242-8723

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  

 

  [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     

 

  

 

  

Section 7.01   (Regulation FD Disclosure) 

On April 17, 2013, the registrant publicly issued a press release announcing it shipped its first Edition 3 CE marked LuViva® Advanced Cervical Scan unit to its distributor in Turkey as more fully described in the press release, a copy of which is furnished as Exhibit 99.1 hereto and which information is incorporated herein by reference.

Item 9.01      Financial Statements and Exhibits.

(d) Exhibits.

     
Number Exhibit
  99.1 Press Release dated April 17, 2013
     

 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

     GUIDED THERAPEUTICS, INC.  
       
    By:  /s/ Mark L. Faupel, Ph.D.  
      Mark L. Faupel, Ph.D.  
      CEO & President  
  Date: April 17, 2013      

 

  

2